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Summary
Development of antiangiogenic therapies would be significantly facilitated by quantitative surrogate pharmacodynamic
markers. Circulating peripheral blood endothelial cells (CECs) and/or their putative progenitor subset (CEPs) have been
proposed but not yet fully validated for this purpose. Herein, we provide such validation by showing a striking correlation
between highly genetically heterogeneous bFGF- or VEGF-induced angiogenesis and intrinsic CEC or CEP levels measured
by flow cytometry, among eight different inbred mouse strains. Moreover, studies using genetically altered mice showed
that levels of these cells are affected by regulators of angiogenesis, including VEGF, Tie-2, and thrombospondin-1. Finally,
treatment with a targeted VEGFR-2 antibody caused a dose-dependent reduction in viable CEPs that precisely paralleled
its previously and empirically determined antitumor activity.
Introduction localized “sprouting angiogenesis.” In addition, there is thought
to be an alternative source for some of the endothelial cells
Antiangiogenic therapy is emerging as a promising treatment comprising newly forming blood vessel capillaries, namely bone
strategy, particularly when combined with chemotherapy for the marrow, from which putative VEGF receptor-2-positive endo-
treatment of certain malignancies, e.g., metastatic colorectal thelial progenitor cells (EPCs) can be mobilized by various cyto-
carcinoma (Hurwitz et al., 2004). The process that is the target kines or growth factors, including VEGF (Asahara et al., 1999).
of this therapeutic approach—formation of new blood vessel These cells enter the peripheral blood circulation to become
capillaries in tumors—is thought to be governed primarily by circulating endothelial progenitors (CEPs) and subsequently in-
the balance of proangiogenic growth factors, such as vascular
corporate into distal sites of ongoing sprouting angiogenesis,endothelial growth factor (VEGF) and endogenous inhibitors of
where they can differentiate into mature endothelial cells (Asa-angiogenesis, e.g., thrombospondin-1 (TSP-1) (Hanahan and
hara et al., 1997; Rafii et al., 2002; Lyden et al., 2001). ThisFolkman, 1996; Bouck et al., 1996; Kerbel and Kamen, 2004).
systemic process is referred to as adult or postnatal vasculogen-Many of the known proangiogenic regulators act as signaling
esis, and it appears to variably contribute to the growth andmolecules to induce the division and migration and promote
development of new blood vessels, including the neovascula-the survival of new differentiated endothelial cells from adjacent
mature host vasculature, which together initiate the process of ture of tumors (Rafii et al., 2002; Ruzinova et al., 2003; Sikder
S I G N I F I C A N C E
The early phases of anticancer drug development, especially cytotoxic chemotherapeutic agents, have been largely guided by
induction of dose-limiting toxicities and objective responses. In contrast, most antiangiogenic drugs do not cause significant tumor
shrinkage and frequently have optimal therapeutic activity below a maximum tolerated dose, when such a dose can be defined.
Thus, alternative surrogate pharmacodynamic markers of activity are urgently needed; a blood test would be ideal in this regard.
Our results bolster the rationale of using circulating peripheral blood VEGFR-2 subpopulations as valid cellular surrogates for the
highly complex process of new blood vessel formation and its therapeutic inhibition, including determination of optimally efficacious
doses for antiangiogenic drugs, or treatment strategies.
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et al., 2003; Lyden et al., 2001). CEPs represent a subset of sels to become endothelial cells. Such adherent cells may in-
clude monocytes, macrophages, or pericyte precursors (Ziegel-mature VEGF receptor-2-positive circulating endothelial cells
(CECs) also found in peripheral blood (Bertolini et al., 2003). hoeffer et al., 2004; Voswinckel et al., 2003; Rehman et al.,
2003; Rajantie et al., 2004; Gothert et al., 2004; Heil et al., 2004).From a cancer treatment perspective, there are a number
of reasons for the current interest in circulating peripheral blood Yet another source of controversy comes from some recent
studies using spontaneously arising mouse tumors, which, de-cells that contribute to angiogenesis, but two in particular stand
out. First, it now appears that various antiangiogenic drugs, or pending on tumor type and stage of disease, appear in some
cases to be much less dependent on bone marrow-derivedtreatment strategies, may work, at least in part, by interfering
with the systemic process of CEP mobilization and function, CEPs for tumor growth, in comparison to subcutaneous trans-
plantable tumor models (Ruzinova et al., 2003; Sikder et al.,and not necessarily only through suppression of local sprouting
angiogenesis (Stoll et al., 2003; Bertolini et al., 2003; Schuch 2003; Li et al., 2004). Thus, it is clear that further studies are
required to show that circulating CECs and CEPs can be usedet al., 2003). Second, assessment of levels of these cells, either
CEPs or CECs, has the potential to be used as a much-needed as valid biomarkers for angiogenesis and antiangiogenic drug
activity. This was the main purpose of our experiments.surrogate pharmacodynamic marker to monitor antiangiogenic
drug activity (Willett et al., 2004); if so, evaluation of these cells The first approach we took to assess circulating VEGFR-2
CECs and putative CEPs as valid peripheral blood cellular mark-might also be used to determine the optimal biologic/therapeutic
dose for antiangiogenic drugs. ers of angiogenesis was based on the genetic heterogeneity of
the angiogenic response in mice. Among the many mechanismsThe problem associated with selecting an efficacious dose,
or to be more precise, an optimal biologic dose (OBD), for many, that can affect the ability to respond to anticancer drugs—
including antiangiogenic agents—are host pharmacogenomicif not most, antiangiogenic drugs or treatments deserves special
mention, as it represents one of the more serious challenges to factors (Rohan et al., 2000). For example, in a seminal study by
Rohan et al., a total of 31 different inbred strains of mice, includ-the successful clinical development of such drugs (Cristofanilli et
al., 2002; McDonald et al., 2004; Parulekar and Eisenhauer, ing F1 hybrids, were analyzed for their relative ability to induce
a basic fibroblast growth factor (bFGF)- or VEGF-mediated angi-2004). The reason is that many such drugs have optimal thera-
peutic activity below a maximum tolerated dose (MTD), when ogenic response, using the corneal neovascular micropocket
assay (Rohan et al., 2000). Variation of up to 10-fold was ob-such a dose can actually be defined; in addition, it is not common
to detect rapid “objective tumor responses,” i.e., tumor shrink- served, with some strains, such as C57BL/6J, being relatively
deficient and others, such as 129/SvImJ, showing strong angio-age of 50% or more in a significant percentage of treated pa-
tients when treating advanced stage cancers with an antiangio- genic responsiveness (Rohan et al., 2000).
Given these aforementioned results, we asked if a similargenic drug alone (Cristofanilli et al., 2002). Such criteria—MTD/
dose-limiting toxicities, and rapid tumor shrinkage—have been genetic heterogeneity exists with respect to the potential to
mediate vasculogenesis and, if so, whether it parallels angiogen-used as surrogates for decades to establish the clinical doses
used for conventional cytotoxic chemotherapy drugs (Cristofan- esis. An affirmative answer would strengthen the hypothesis
that VEGFR-2 peripheral blood circulating cells contribute toilli et al., 2002; Park et al., 2004). Thus, alternative surrogate
markers are needed to help select the optimal doses for many the formation of new blood vessels and would provide further
compelling rationale for evaluating levels and viability of putativedifferent antiangiogenic drugs or treatments, in order to mini-
mize the level of empiricism in their clinical development; mea- CEPs as a useful pharmacodynamic surrogate marker not only
for monitoring the activity of antiangiogenic treatment strategiessuring CECs/CEPs in samples of peripheral blood could clearly
represent such a marker for antiangiogenic agents. (Bertolini et al., 2001, 2003; Willett et al., 2004), but also for
determining the all important optimal biologic dose. AddressingHowever, there is considerable controversy about the nature
and function of putative circulating endothelial progenitor cells, the latter point constituted a second approach for our studies,
in which we undertook retrospective and concurrent dose re-and as a consequence, their usefulness as surrogate pharmaco-
dynamic markers of angiogenesis could be called into question. sponse studies with an antiangiogenic drug to determine
whether a strict correlation exists between optimal antitumorFor example, based on transplantation studies in mice using
genetically marked donor bone marrow cells transferred to syn- dose and the suppressive effects on VEGFR-2peripheral blood
cells.geneic, lethally irradiated recipients, estimates of the levels of
genetically marked integrated marrow-derived endothelial cells We therefore tested a large number of different inbred strains
of mice for intrinsic levels of nonhematopoietic CEPs, i.e.,in newly formed blood vessels have been reported to be as
high as 50% (Garcia-Barros et al., 2003), while other studies CD13/VEGFR-2/CD45/CD117 in peripheral blood using a
four-color flow cytometry assay (Bertolini et al., 2003), which weshow somewhat lower, but nevertheless substantial levels, e.g.,
10%–20% (Asahara et al., 1997; Crosby et al., 2000); in contrast, term the intrinsic “peripheral blood vasculogenic phenotype.” In
addition, we measured levels of nonhematopoietic CECs, i.e.,other studies report much lower levels, e.g., 5% to essentially
nondetectable (Ziegelhoeffer et al., 2004; Machein et al., 2003). CD13/VEGFR-2/CD45, of which CEPs represent a subset.
Our results show a pronounced heterogeneity of the intrinsicOne recently proposed explanation to account for these variable
results raises a potentially significant challenge to the concept levels of CEPs or CECs per milliliter of blood, the nature of
which is remarkably correlated with the angiogenesis resultsof adult vasculogenesis. It is based primarily on the application
of more definitive cell detection methods, such as laser-scan- reported by Rohan et al. (2000), as well as new results we report
here. Furthermore, additional results suggest that both CEP andning confocal microscopy, that have shown that various types
of angiogenesis-promoting bone marrow-derived circulating CEC heterogeneity may be explained, at least in part, by the
action of well-known stimulators and inhibitors of sproutingperipheral blood cells can adhere very closely to the lumen of
new blood vessels—but not actually integrate within such ves- angiogenesis, such as VEGF and TSP-1. Finally, we show a
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striking retrospective analysis of the utility of measuring CEPs Table 1. Corneal neovascular area induced by VEGF in different mouse
strainsin relation to the problem of establishing optimal biologic antian-
giogenic drug dose, using a validated and specific VEGF recep- Strain Vessel area induced
by 180 ng VEGFtor-2 (flk-1)-targeted antiangiogenic agent. Taken together, the
results show that measuring VEGFR-2 peripheral blood cells 129/SvImJ 2.2  0.4**
can be used as a surrogate for the complex process of angio- DBA/2J 1.4  0.3**
BALB/cJ 1.0  0.2**genesis and its therapeutic inhibition, including establishing the
FVB/NJ 0.9  0.1*optimal biologic dose for targeted antiangiogenic drugs.
CBA/J 0.8  0.1
C57BL/6J 0.8  0.2
Results C3H/HeJ 0.8  0.1
CD-1 0.8  0.2
Background to the experimental approach The average vessel area (mean  SD) in mm2 in response to pellets of 180
and rationale ng VEGF is listed for various strains of mice (n  9 eyes/strain). The strains
are ranked (highest to lowest). *Significantly different (p 0.05) from C57BL/In previous studies, some of us (F.B., Y.S., R.S.K.) have used
6J; **significantly different (p  0.05) from all other strains.four-color flow cytometry to detect CECs, designated as
CD13/VEGFR-2/CD45, and CEPs that have a similar pheno-
type except for being positive to c-kit (i.e., CD117), which is
present on stem cells and progenitors (Bertolini et al., 2003;
Capillo et al., 2003; Monestiroli et al., 2001). As the main purpose Assessment of CECs/CEPs in the peripheral blood
of different inbred mouse strainsof these studies was to assess whether measurement of such
cells represents a valid surrogate approach for neovasculariza- We next undertook an analysis of levels of CECs/CEPs among
eight different inbred mouse strains, selecting strains represen-tion and not to elucidate their precise angiogenic function or
identity, we adopted the following strategy: (1) assess whether tative of “high,” “medium,” and “low” angiogenic respon-
siveness, as assessed by the corneal micropocket angiogenesislevels of CECs and/or CEPs are genetically heterogeneous; (2)
determine if such heterogeneity retrospectively tracks with pre- assay. For this purpose, a group of 9- to 12-week-old males
from different mouse strains, as summarized in Figure 1, wereviously determined-induced angiogenesis results in the eye or
prospectively induced angiogenesis stimulated by bFGF subcu- examined for levels of CECs (Figure 1A) and CEPs (Figure 1B),
by using flow cytometry (as described in the Experimental Pro-taneously and measured by a perfusion assay, or by VEGF in
the eye; (3) evaluate whether several well-known and validated
molecular regulators of angiogenesis also regulate intrinsic lev-
els of CECs and CEPs; (4) assess if the previously determined
optimal therapeutic (antitumor) dose of a targeted antiangio-
genic drug is accurately reflected by measurements of declines
in CEPs; and (5) determine if CECs and CEPs are significantly
reduced in tumor-bearing mice by the same targeted drug at
the optimal dose.
Sprouting angiogenesis among different inbred mouse
strains in the corneal neovascular micropocket
assay induced with VEGF
Measurement of sprouting angiogenesis in numerous inbred
mouse strains was previously assessed by Rohan et. al. using
a corneal neovascular micropocket assay with bFGF as the
stimulus (Rohan et al., 2000). We conducted a similar experi-
ment in which we examined eight inbred mouse strains and
assessed sprouting angiogenesis using the same method, i.e.,
corneal neovascular micropocket assay, but in this case we
used 180 ng VEGF as the stimulus, instead of 10 ng bFGF (as
described in the Experimental Procedures). The results in Table
1 show that the sprouting vessel area on the cornea induced
by 180 ng VEGF pellets is comparable to the results that were
reported previously (Rohan et al., 2000). Both VEGF and bFGF
pellets have shown a range of up to 10-fold differences in the
ability to induce angiogenesis. Thus, a strain such as 129/SvImJ,
which was previously shown to have strong angiogenic ability
using the bFGF as the angiogenic stimulus, was found to have
strong angiogenic ability when VEGF was used as the stimulus.
Figure 1. The evaluation of CECs/CEPs in different mouse strains
Similarly, strains such as C57BL/6J, C3H/HeJ, and CD-1, pre-
Four to six males per group, 9–12 weeks of age, from different mouse strains,viously shown to express low levels of bFGF-induced angio-
as described in the figure, were bled by cardiac puncture and evaluated
genic responsiveness, had a similar limited ability to induce for the number of CECs (A) and CEPs (B) in 1 l peripheral blood (PB) using
a four-color flow cytometry assay.angiogenesis when VEGF was used as the stimulus.
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Figure 2. The correlation between angiogenic
responses evaluated either by VEGF or bFGF with
the number of peripheral blood CECs/CEPs
Correlation with angiogenic responsiveness was
conducted by plotting the results obtained
from the corneal neovascular micropocket
assay and the levels of CEC/CEP. x axis values
represent the average (mean  SD) of neovas-
cularization vessel area in mm2 stimulated by ei-
ther 180 ng VEGF (results from Table 1) or 10 ng
bFGF, as previously reported (Rohan et al., 2000).
y axis values represent the baseline number
(mean  SD) levels of cells/l peripheral blood
of either CECs (from Figure 1A) or CEPs (from
Figure 1B) of the same strains.
cedures). The results in Figure 1 demonstrate a striking correla- duced with 10 ng bFGF (Rohan et al., 2000) and our prospective
tion between the angiogenic ability assessed by the corneal evaluation of the number of CECs/CEPs (r  0.93, p  0.006
neovascular micropocket assay and the absolute number of for CECs; r  0.97, p  0.002 for CEPs).
CECs. Thus, the 129/SvImJ mouse strain, shown to have the
strongest angiogenic ability among the strains tested (Table 1 Relative angiogenic ability evaluated by a Matrigel
and Rohan et al., 2000), also expressed the highest numbers plug perfusion assay
of CECs. In contrast, mice of C57BL/6J, C3H/HeJ, and CD-1
In order to show that the angiogenesis results are not restricted
strains, all of which were shown to have significantly less angio-
to this particular assay and the ophthalmic environment, wegenic ability (Table 1 and Rohan et al., 2000), were found to
used a different method, i.e., the Matrigel (subcutaneous) plughave much lower numbers of CECs (Figure 1A). A range of
perfusion assay (as described in the Experimental Procedures)approximately 20-fold was found among the various strains we
to measure the angiogenic ability in some of the mouse strainstested. Moreover, we also observed a correlation between the
that we studied for levels of CECs/CEPs. For this approach,number of CECs and CEPs. Thus, 129/SvImJ that presents with
three mouse strains, 129/SvImJ, BALB/cJ, and C57BL/6J,high levels of CECs (11–32 cells/l peripheral blood) also had
which demonstrated high, mid, and low levels of CECs/CEPshigh levels of CEPs (3–7 cells/l in the peripheral blood). In
and angiogenic ability using the eye assay, respectively, werecontrast, strains that were shown to have mid or low levels of
CECs were found to have the lowest levels of CEPs. The nature tested using the Matrigel plug perfusion assay.
of this correlation suggests that both angiogenesis and the Figure 3 shows the ratio between Matrigel plug fluorescence
vasculogenic phenotype are likely regulated by the same genetic and plasma fluorescence. This ratio was the highest (0.0036) in
heterogeneity among different mouse strains. Similar results the 129/SvImJ strain, which also has shown the highest levels
were obtained when female mice were used (data not shown). of both CECs/CEPs and the strongest ability to induce angio-
A comparison was undertaken between both CECs or CEPs genesis in the corneal neovascular micropocket assay (Figure
with the corneal neovascular micropocket assay results induced 1 and Table 1, respectively). In contrast, the C57BL/6J mouse
by 180 ng VEGF, this time in a prospective analysis (Table strain, which demonstrated a low angiogenesis/vasculogenic
1); the results again revealed a striking correlation, which was phenotype (Figure 1), was also found to have a low ratio between
confirmed by using the nonparametrical Spearman test (r 
Matrigel plug fluorescence and plasma fluorescence (0.0014).
0.85, p  0.01 for CECs; r  0.87, p  0.007 for CEPs). The
The results from the Matrigel plug perfusion assay showed asame correlation was found among strains having mid and low
statistically significant difference between 129/SvImJ mice andangiogenic ability, as shown in Table 1, and as previously re-
C57BL/6J mice (p  0.002). Consistent with this trend, BALB/ported (Rohan et al., 2000). This linear correlation is shown in
cJ mice demonstrated a mid range of angiogenic ability, withFigures 2A and 2B, where we plotted the “angiogenic respon-
respect to intrinsic levels of CECs/CEPs and the Matrigel plugsiveness” results from Table 1 versus the number of CECs or
perfusion assay (0.0024). These results confirm our observa-CEPs per milliliter of blood. In addition, an even stronger and
tions, shown in Figure 1 and Table 1, and suggest that thestriking correlation is shown in Figures 2C and 2D, where we
correlation is not restricted to angiogenic responses induced inplotted the previous reported angiogenic responsiveness results
obtained by the corneal neovascular micropocket assay in- an ophthalmic microenvironment, or to the assay used.
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Figure 3. The assessment of angiogenic ability by a Matrigel plug perfusion
assay
Six males per group (C57BL/6J, BALB/cJ, and 129/SvImJ), age 9–10 weeks,
were assessed for angiogenic ability by a Matrigel plug perfusion assay (as
described in the Experimental Procedures). Mice were divided into two
groups: Matrigel alone, i.e., bFGF (), or in the presence of bFGF (). The
results presented are a ratio between Matrigel plug fluorescence and sys-
temic plasma fluorescence (***p  0.002).
Figure 4. Assessment of CEC and CEP levels in TSP-1 null C57BL/6 mice, VEGF
hypermorphic, and Tie-2-overexpressing mice
A: Ten 10-week-old TSP-1/ C57BL/6J mice were divided into two groups;
five mice were injected with the vehicle only, and five were injected withTSP-1/ C57BL/6J mice demonstrate enhanced
ABT-510 TSP-1 peptide mimetic, and another five age-matched wild-typemobilization of CECs/CEPs
controls were all bled by cardiac puncture and assessed for CECs/CEPsWe next addressed the question of whether the basis of the
by the four-color flow cytometry assay, as described in the Experimental
genetic heterogeneity in levels of CECs and CEPs is, at least Procedures.
in part, regulated by known and validated molecular regulators B:Nine- to twelve-week-old VEGF hypermorphic or Tie-2-overexpressing and
CD-1 strain background control male mice (n  4–6) were analyzed forof sprouting angiogenesis, either stimulators such as VEGF or
CEC/CEP levels by four-color flow cytometry assay, similar to the analysisinhibitors such as TSP-1. To do so, we used primarily an in vivo
conducted for TSP-1/ mice. Black asterisks: ***p  5.7  105; **p  0.024;genetic approach and assessed levels of the cells in various
* p 0.61. Gray asterisks: ***p 0.0011; *p 0.29 from background control.
mutant (knockout) or transgenic mouse models. First, we evalu-
ated a mutant of the C57BL/6J mouse strain (which normally
expresses low angiogenic ability relative to most other evaluated
strains [Rohan et al., 2000]) that has a targeted disruption in namely VEGF or Tie-2, on intrinsic levels of CECs/CEPs. To do
the tsp-1 gene (Lawler et al., 1998). TSP-1 is a well-known so, we analyzed peripheral blood either from VEGF hypermor-
endogenous inhibitor of angiogenesis (Bouck et al., 1996), but phic (VEGF-Ahi/) (Miquerol et al., 2000) or Tie-2-overexpressing
its effect on CEPs and CECs has not yet been determined. The mice (Sarao and Dumont, 1998; Maisonpierre et al., 1993).
results shown in Figure 4A indicate that the numbers of both VEGF-Ahi/mice (kindly provided by Dr. Andras Nagy, University
CECs and CEPs are approximately 5-fold higher in the TSP-1 of Toronto, Canada) have a 2- to 3-fold increase in circulating
null C57BL/6J mice (p  0.024, p  0.0005, respectively), rela- VEGF levels during embryonic development (Miquerol et al.,
tive to the C57BL/6J control mice. In addition, to confirm that 2000) as well as in adulthood (Y.S. and D.C., unpublished data).
TSP-1 has a direct effect on levels of CECs/CEPs, we undertook In addition, angiopoietin-1 and -2 binding Tie-2 is a highly endo-
a pharmacologic “knockout” approach in which TSP-1 null mice thelial cell-specific receptor tyrosine kinase that is essential for
were treated on a daily basis with the antiangiogenic drug ABT- embryonic vascular development (Sato et al., 1995; Maison-
510, a peptide mimetic derived from the type I (properdine-like) pierre et al., 1993). Embryos lacking Tie-2 signaling pathways
repeats of TSP-1 that mimics the interaction between TSP-1 result in lethality due to impaired cardiac function and vascular
and CD36 receptors (Reiher et al., 2002; Viloria-Petit et al.,
hemorrhaging (Sarao and Dumont, 1998). The background of2003). After 2 weeks of daily administration with either ABT-
both of these mutant mouse strains is CD-1, which was pre-510 peptide or the vehicle (5% dextrose in water), mice were
viously shown to have low angiogenic responsiveness (Rohanevaluated for CECs/CEPs. Figure 4A shows that the treatment
et al., 2000) and, by us, to have low levels of CECs/CEPs. Maleof TSP-1 null mice with ABT-510 results in a marked reduction
mice, 9–12 weeks old, from either VEGF-Ahi/, Tie-2 transgenic,of the intrinsically high CEC/CEP levels. The daily dose selected
or CD-1 background groups were anesthetized, bled by cardiacfor this experiment (60 mg/kg/day) was known to be in the range
puncture, and blood prepared for the evaluation of CECs/CEPs.of an optimal biologic dose (J.H., unpublished data).
The results in Figure 4B show that VEGF-Ahi/ as well as mice
overexpressing Tie-2 receptor exhibit a 7- to 8-fold increase inVEGF-Ahi/ as well as CD-1 Tie-2 transgenic mice have
CEC levels in comparison to CD-1 wild-type controls (p 7.8increased mobilization and viability of CECs/CEPs
105, p  0.001, respectively); similarly, there was a markedIn order to extend the aforementioned findings, we next evalu-
ated two different stimulatory regulators of angiogenesis, elevation levels of CEPs (p  0.005, p  5.8  105, respec-
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Figure 5. The assessment of viable CEPs analyzed
in a dose response of DC101 in Lewis lung carci-
noma (LL/2) C57BL/6J and Namalwa lymphoma
CB-17 NOD/SCID mice
LL/2 C57BL/6J (n  5/group) or Namalwa CB-17
NOD/SICD (n  6/group) treatments were initi-
ated with escalating doses (0–2000g) of DC101
as indicated in the figure. The LL/2-bearing mice
were sacrificed after a week of DC101 adminis-
tration, and blood was drawn by cardiac punc-
ture for the assessment of viable CEPs (A). Tumor
volumes were measured in all groups (C). The
Namalwa-bearing mice were bled from the or-
bital sinus for the evaluation of CEPs (B) and mea-
sured for their tumor growth (D) every 5 days up
to 5 weeks of treatment. PB, peripheral blood.
tively). Interestingly, in the Tie-2-overexpressing mice, a very wett et al., 1999) and, more recently, using the HT29 human
colon xenograft model in nude mice (Bocci et al., 2004). Wemarked increase of approximately 60-fold in the levels of CEPs
(from 0.1 cells/l in the wild-type to 6 cells/l in mice overex- therefore undertook a retrospective analysis in order to test
whether the evaluation of CECs/CEPs can, in principle, helppressing Tie-2) was observed. The percentage of the CEP sub-
population (approximately 75%), from the general CEC popula- establish an optimal dose of such an antiangiogenic drug. To
do so, we first evaluated the viability of CEPs in two differenttion, was found to be the highest among all genetically altered
mice we have tested thus far. Moreover, these results further tumor models. We tested the effect of DC101 in escalating
doses (0–2000 g/mouse/dose) on a syngeneic Lewis lung car-support a role for Tie-2 in adult vasculogenesis primarily by
priming endothelial cell progenitor mobilization, as shown by cinoma in C57BL/6J mice, and on a human lymphoma (Na-
malwa) xenograft in CB-17 NOD/SCID mice.increased levels of the CEPs, and are in line with recent reports
showing that Tie-2 is expressed by putative CEPs (Shaw et al., Since the effect of DC101 is to block VEGFR-2, we first
tested whether a possible interference might exist between our2004).
Furthermore, since the absolute number of CECs/CEPs is flow cytometry flk-1 (VEGFR-2)-directed antibody (purchased
from BD Biosciences) and the DC101 (anti-VEGFR-2 blockingcalculated using the WBC count multiplied by the percentage
of CECs or its CEP subset, we asked whether any correlation antibody). Blood pooled from five mice was incubated with 20
ng–2 mg of DC101 for 1 hr (as recommended by the manufac-exists between the WBC count and potential angiogenic respon-
siveness in different strains or transgenic mice we studied (Sup- turer), and then samples were analyzed for CECs/CEPs ac-
cording to the Experimental Procedures. No blocking was de-plemental Table S1 at http://www.cancercell.org/cgi/content/
full/7/1/101/DC1/). We found that there was no significant corre- tected between the different samples, since an equal number
of events was observed in the CD13/CD45 and VEGFR-2/lation between WBC counts and the absolute number of CECs/
CEPs. CD45 gates at all DC101 concentrations tested (data not
shown).
Next, we evaluated levels of viable CEPs after DC101 treat-Strict correlation of antiangiogenic drug dose response
with respect to antitumor therapeutic activity and ment in both LL/2 tumor-bearing C57BL/6J and Namalwa xeno-
graft CB-17 NOD/SCID mice. To do so, either 10-week-oldeffects on peripheral blood VEGFR-2 CEPs
There are several reports showing suppressive effects of various C57BL/6J mice transplanted with LL/2 tumor cells or 6- to
8-week-old CB-17 NOD/SCID mice transplanted with Namalwaantiangiogenic drugs on the CECs/CEPs, e.g., reduction in the
viability and/or mobilization of CEPs, both preclinically (Capillo lymphoma cells were assessed for tumor volumes according to
the Experimental Procedures. When the tumor volume reachedet al., 2003; Bertolini et al., 2003; Schuch et al., 2003) and
clinically (Willett et al., 2004). In this regard, empirical dose approximately 200 mm3, mice (n 5–6/group) were treated with
DC101 in escalating doses, i.e., 0, 200, 400, 800, 1200, andresponse preclinical studies with DC101, a rat monoclonal
blocking antibody specific for the mouse VEGFR-2 (flk-1) recep- 2000 g/mouse either for 1 week (i.e., three injections) in the
LL/2 model or for 5 weeks (injected every 3 days) in the Namalwator (Prewett et al., 1999; Bocci et al., 2004), have shown that
the optimal antitumor therapeutic dose of DC101 is in the range model. LL/2 C57BL/6J mice were sacrificed 24 hr after the
last injection, blood was drawn by cardiac puncture for theof 800 g–1 mg/mouse, administered every 3 days. In two such
studies, the dose response analysis was undertaken using the assessment of viable CEPs, and tumor volumes were measured.
In the case of Namalwa CB-17 NOD/SCID mice, blood wasLewis lung carcinoma grown in syngeneic C57BL/6J mice (Pre-
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0, 5, 10, 30, 60, 90, and 120 mg/kg/day. Twenty-four hours
after the last injection, mice were sacrificed, and blood was
drawn by cardiac puncture for the assessment of the viable
CEPs in a manner similar to tumor-bearing mice that were
treated with DC101. The results in Figures 6C and 6D show
that either 800 g/mouse of DC101 or 60 mg/kg/day of ABT-
510 appear to be optimal biological doses, respectively, since
they induced the lowest level of viable CEPs. This is similar to the
reduction in the viable CEPs that we observed in LL/2 C57BL/6J
mice and Namalwa CB-17 NOD/SCID mice and is also consis-
tent with the optimal dose of ABT-510 (J.H., unpublished data).
In addition, we tested the optimal biologic dose of either
DC101 or ABT-510 in different strains to determine whether
similar effects are detected in “high angiogenic strains” such
as 129/SvImJ or “low-angiogenic” strains such as C57BL/6J,
i.e., regardless of the genetic background. Both DC101 and
ABT-510 (Figures 6E and 6F, respectively), caused a similar
marked reduction in the viable CEPs in all three strains, declining
to basal levels of approximately 0.1 viable CEPs/l peripheral
blood.
Both DC101 and ABT-510 reduce the levels of viable
CEPs in different and diverse modelsFigure 6. Evaluation of viable CEPs in different strains (non-tumor-bearing)
treated with either DC101 or ABT-510 of tumor-bearing mice
In addition to retrospectively showing the optimal antiangio-C57BL/6J (A), CB-17 NOD/SCID (B), and BALB/cJ (C and D) mice (n  5–6/
group) were treated with either DC101 in doses of 0–2000 g/mouse or ABT- genic dose of either DC101 or ABT-510 in BALB/cJ mice and
510 in doses of 0–120 mg/kg/day, as indicated in the figure. In addition, the impact of both drugs at the optimal dose on the reduction
C57BL/6J and 129/SvImJ strains were treated in the optimal dose with either of viable CEPs in different strains representing low, mid, andDC101 in 800 g/mouse (E) or ABT-510 in 60 mg/kg/day (F). In all cases,
high angiogenic ability, we asked whether either 800 g/mouseafter a week of treatment, mice were sacrificed and analyzed for the
CEC/CEP levels by four-color flow cytometry assay, similar to the analysis of DC101 or 60 mg/kg/day of ABT-510 would have a significant
conducted in Figures 4 and 5. PB, peripheral blood. effect on the CECs/CEPs in different mouse tumor models simi-
lar to what has been previously observed for certain other antian-
giogenic drugs or treatments (Schuch et al., 2003; Bertolini
et al., 2003; Capillo et al., 2003). We tested a spontaneous
drawn from the orbital sinus every 5 days for the assessment erythroleukemia model in BALB/cJ (Figure 7A), an orthotopic
of viable CEPs and measured for tumor volumes as well. The human breast cancer (MDA-MB-231) xenograft model in CB-
results show that 800g/mouse of DC101 is the optimal biologi- 17 SCID mice (Figure 7B), and a subcutaneously implanted,
cal dose in both LL/2 C57BL/6J model (Figure 5A) and Namalwa syngeneic Lewis lung carcinoma (LL/2) model in C57BL/6J mice
lymphoma CB-17 NOD/SCID model (Figure 5B), since it induced (Figures 7C and 7D). In each case, mice were divided into two
the lowest level of viable CEPs and greatest decrease in tumor groups (n  5/group). One group was injected for a week with
volume (Figures 5C and 5D, respectively). These results were either DC101 antibody (every 3 days, except in the erythroleuke-
not altered by further escalating the DC101 dose up to 2000 mia model where mice were treated for 3 weeks, after which
g/mouse. an antitumor effect was observed), or ABT-510 peptide (once
Since the CEP levels are elevated by tumor growth as can a day), while the other (control) group was injected with the
be seen in Figure 5B, this raises the possibility that the reduction respective vehicle only (PBS for DC101 and 5% dextrose in
in the viable CEPs is due to the tumor volume changes, as a water for ABT-510) as an untreated control arm. In all tumor
secondary effect and not to the optimal biological dose of the models, an increase in the levels of both CECs and CEPs was
drug. Therefore, we evaluated the viable CEPs in a correlation found in the tumor-bearing mice in comparison to the back-
study in non-tumor-bearing mice. First, we performed a DC101 ground normal control mice (data not shown). In addition, a
dose response study in both tumor-free background mice that significant increase, i.e., 10-fold for erythroleukemia model (Fig-
we have tested above (i.e., C57BL/6J and CB-17 NOD/SCID). ure 7A; p  0.017), 20-fold for MDA-MB-231 human xenograft
In both cases, DC101 in escalating doses has shown that the model (Figure 7B; p  0.047), and approximately 7- to 10-fold
optimal dose is 800 g/mouse, since it induced the greatest for Lewis lung carcinoma model (Figures 7C and 7D; p  0.02),
reduction in the viable CEPs (Figures 6A and 6B, respectively) was in each case detected with respect to the viability and
that was not altered using higher doses. Second, we tested the mobilization of CEPs. Both DC101 and ABT-510 treatments
viable CEPs in other strains and also with another drug—ABT- caused a reduction in the number of CECs/CEPs (data not
510, a TSP-1 peptide mimetic. For this approach, 10-week-old shown) as well as in the viable CEPs, and indeed, the levels
tumor-free BALB/cJ mice (n  5/group) were injected either were not significantly different from values detected in normal
three times (once every 3 days) with DC101 in escalating doses controls, as shown in Figure 7 (p  0.16), with the exception
(similar to tumor-bearing mice, i.e., 0, 200, 400, 800, 1200, and of ABT-510 treatment in LL/2 mice, which showed a reduction
in viable CEP levels that was significantly different from the2000 g/mouse), or for a week (once a day) with ABT-510 at
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sured by two different assays. Third, two of the best character-
ized stimulators of sprouting angiogenesis, i.e., VEGF and Tie-2,
as well as a well-known endogenous angiogenesis inhibitor
(TSP-1), appear to also regulate the intrinsic levels of the two
peripheral blood circulating cell types we measured in our exper-
iments. Fourth, a dose-dependent decrease in these cell types
was induced in three different mouse strains by a well-character-
ized, validated, and highly specific targeted antiangiogenic
drug—the DC101 monoclonal antibody to mouse VEGFR-2—in
a manner that strikingly correlated with its dose-dependent bio-
logic activity, including its known optimal biologic dose; more-
over, this was observed in either normal or tumor-bearing mice
using several different strains. In addition, a dose response with
TSP-1 peptide mimetic antiangiogenic drug (ABT-510) showed
a marked reduction in the range of a known optimal dose, i.e.,
60 mg/kg/day. Fifth, the drugs were also shown to be similarly
efficacious in their suppressive effects on both CECs and CEPs
when tested at the optimal dose in high, mid, and low angiogenic
strains (e.g., 129/SvImJ, BALB/cJ, and C57BL/6J, respectively).
Figure 7. The viability of CEPs in various tumor-bearing mouse models Finally, we also show that both DC101 and ABT-510, at an
treated with either DC101 or ABT-510 in their optimal doses optimal dose, have potent suppressive activity on these two
Mice induced with erythroleukemia (A), MDA-MB-231 human breast cancer circulating cell types in four different tumor mouse models,
(C), or Lewis lung carcinoma (B and D) were divided into two groups (n  which included a spontaneous (nontransplanted) leukemia, a
5/group); one group was treated with either DC101 or ABT-510 in the optimal
syngeneic lung tumor, a transplanted human breast cancer xe-dose (i.e., 800g/mouse for DC101 and 60 mg/kg/day for ABT-510), whereas
nograft, and a human Burkitt’s lymphoma; in all cases, a markedthe other group was injected with the vehicle (PBS for DC101 and 5% dex-
trose in water for ABT-510), and another group age-matched wild type reduction in the viable CEPs was observed, down to baseline,
controls. Mice were bled by cardiac puncture and assessed for viable CEPs control levels in most cases.
according to the Experimental Procedures. ***p  0.01; **0.05  p  0.01;
Our results do not directly address the current controversy*p  0.05, from background control. PB, peripheral blood.
surrounding the validity of the concept of circulating bone mar-
row-derived endothelial “progenitor” cells, which have been hy-
pothesized to integrate into newly forming blood vessels and
differentiate into mature endothelial cells, thus contributing tobackground control but nevertheless still significantly different
new blood vessel formation, i.e., “systemic vasculogenesis”from the untreated tumor-bearing control mice (p  0.009).
(Stoll et al., 2003; Jain and Duda, 2003). As cited in the Introduc-Thus, in all of these tumor models—which involved spontaneous
tion, several recent reports, some based on confocal micros-and transplanted tumors, both solid and leukemic, and in differ-
copy techniques, have questioned the authenticity or relativeent mouse strains—we found marked increases of CECs and
importance of this concept and have in some cases insteadCEPs in tumor-bearing mice, which were reduced to back-
implicated circulating bone marrow-derived cells, which stimu-ground levels using the optimal dose range of two very different
late neovascularization after homing to sites of angiogenesisantiangiogenic drugs, one an antibody and the other a peptide,
and adhering closely to the endothelial cells of the newly forminghaving distinctly different endothelial cell molecular targets.
vessels (Ziegelhoeffer et al., 2004; Voswinckel et al., 2003; Reh-
man et al., 2003; Rajantie et al., 2004; Gothert et al., 2004; HeilDiscussion
et al., 2004). In this regard, our results, taken together, strongly
support the hypothesis that there are measurable, defined circu-Our results regarding measurements of CD13/VEGFR-2/
lating peripheral blood VEGFR-2 cells that in all likelihood func-CD45/CD117 peripheral blood circulating cells, historically
tionally contribute to angiogenesis, whether such cells are trueconsidered to be bone marrow-derived CEPs and CD13/
endothelial progenitors or vessel adherent “support” cells suchVEGFR-2/CD45 cells, designated as mature CECs, are of
as monocytes, macrophages, or precursor pericytes. Regard-considerable importance with respect to the question of whether
less of their quantitative contribution to angiogenesis, the resultssuch cell types (or perhaps more importantly, whether circulat-
are strongly supportive of assessing their levels as valid surro-ing VEGFR-2 peripheral blood cells in general) in all probability
gate markers of angiogenesis, including assessing the effectsfunctionally contribute to angiogenesis and can be used reliably
of antiangiogenic agents or treatments. As such, the conclusionas valid quantitative surrogate markers of angiogenesis and
reached in several previous studies—that an antiangiogenic ef-antiangiogenic drug activity. Thus, we report here five results
fect was achieved based on declines of the types of circulatingrelevant to providing an affirmative answer to this question. First,
cell we have measured, after treatment of tumor-bearing miceintrinsic levels of the aforementioned two circulating VEGFR-2
with such drugs as endostatin (Schuch et al., 2003; Capillo etcell types vary significantly, up to 20-fold, between different
al., 2003) or prolonged low-dose metronomic chemotherapymouse strains, i.e., they are highly genetically heterogeneous.
(Bertolini et al., 2003) or treatment of rectal carcinoma patientsSecond, this genetic heterogeneity correlates to a remarkable
with bevacizumab, the humanized anti-VEGF antibody (Willettdegree with the ability of these same strains of mice to respond
et al., 2004)—is supported strongly by our results. This is ato an angiogenic stimulus whether induced by bFGF or VEGF,
both in the ophthalmic or subcutaneous environment, and mea- critical point, because measuring and documenting antiangio-
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In vivo tumor induction and measurementgenic drug activity using a blood-based assay, and establishing
The spontaneous Friend erythroleukemia model has been described pre-the optimal biologic/therapeutic dose of such drugs, would
viously (Shibuya and Mak, 1983). Syngeneic Lewis lung carcinoma (LL/2)greatly aid in their clinical development and application.
model was described previously (Prewett et al., 1999; Bocci et al., 2003).
Because we did not evaluate directly how the two circulating Orthotopic human breast cancer model (MDA-MB-231) was described pre-
VEGFR-2 cell types contribute to angiogenesis, or whether viously (Bocci et al., 2004). Human Burkitt’s lymphoma (Namalwa) model
was described previously (Bertolini et al., 2003). For detailed informationthey integrate into newly formed vasculature, consideration
on tumor models and measurements, see the Supplemental Experimentalmight be given to terminology such as circulating peripheral
Procedures at http://www.cancercell.org/cgi/content/full/7/1/101/DC1/.blood “neovasculature progenitor cells” or “vasculogenic pro-
moting cells,” as these terms could encompass perivascular Pharmacological and biological reagents and dose schedule
adherent/support cells as well as endothelial progenitor cells. A rat anti-mouse neutralizing monoclonal antibody directed to mouse
VEGFR-2 (flk-1) called DC101 was generated by ImClone Systems Inc. (NewRecent clinical results showing similar robust declines in both
York, NY). This antibody was reconstituted in sterile PBS and injected intra-VEGFR-2 CECs and CEPs in a small number of evaluated
peritoneally into mice twice a week, as described in the text and elsewherecancer patients as a result of treatment with bevacizumab are
(Prewett et al., 1999; Klement et al., 2000). Control mice were injected with
especially encouraging in this regard (Schuch et al., 2003), since the vehicle alone (PBS).
they suggest the potential of evaluating such cells in peripheral The nonapeptide Ac-Sar-Gly-Val-D-allo-Ile-Thr-Nva-Ile-Arg-Pro-ethy-
blood samples to monitor clinical antiangiogenic drug activity. lamide, which contains a fragment of the second type-I TSP-1 repeat (ABT-
510 or DI-TSPa), was generated by Abbott Laboratories (Reiher et al., 2002).Our results show that this might now be extended to help deter-
The peptide was dissolved in 5% dextrose and injected intraperitoneally inmine optimal antiangiogenic drug dosing and as such may be
a dose of 60 mg/kg/day into TSP-1 null mice. Control mice were injected
a more tractable and much less expensive approach of doing with the vehicle only (5% dextrose in water).
so compared to such methods as measuring tumor blood flow
and vascular permeability by dynamic contrast-enhanced mag- Statistical analysis
Results are reported as the mean SD. Statistical significance of differencesnetic resonance imaging (DCE-MRI) (Morgan et al., 2003). It is
was assessed by Student-Newman-Keuls test, using the Microsoft Officealso noteworthy that molecular surrogates of circulating VEGFR-
2000 (Microsoft Office-Excel software). The level of significance was set at2 cells such as VE-cadherin (for CECs) measured by RT-PCR
p 0.05. In addition, results from the correlation between corneal neovascu-
of whole RNA in blood or similar molecular-based approaches lar micropocket assay and the numbers of CEC/CEP reported are signifi-
should make evaluation of such cell types more feasible in the cantly correlated with the nonparametrical Spearman test using the
GraphPad Prism v. 4.0 (GraphPad Software). The level of significance wasnear future (Rabascio et al., 2004).
set at Spearman r 	 0.85 and p  0.05.In summary, lack of a validated in vivo assay to measure
angiogenesis has been a major impediment to the clinical devel-
Acknowledgments
opment of many antiangiogenic drugs. Our results reported
herein highlight the possibility of a peripheral blood-based cellu- We thank Cassandra Cheng for her excellent secretarial work. We are grateful
to numerous colleagues for their comments and suggestions regarding thelar assay to both measure and monitor angiogenesis, as well
studies summarized in this manuscript and Dr. Douglas Hanahan for criticalas to monitor antiangiogenic drug activity, the latter of which
reading of the manuscript. This work was supported primarily by grants tocan be exploited to help establish the optimal biologic dose of
R.S.K. from the National Cancer Institute of Canada, and also from the
such drugs. National Institutes of Health (NIH) (CA-41233) and the Canadian Institutes
of Health Research (CIHR). Support was also received from Associazione
Experimental procedures Italiana per la Ricerca sul Cancro (AIRC), Instituto Superiore di Sanita (ISS),
and the 6th EU framework program “Angiotargeting” to F.B. and from
Animal models and strains HL68003 and CA92644 (NIH) to J.L. R.S.K. is a Canada Research Chair in
The analyses of all strains and transgenic mice were performed on groups Molecular Medicine. Y.S. is a recipient of a postdoctoral fellowship award
of four to six males, 9–12 weeks old, unless indicated otherwise (for detailed from the CIHR. D.C. is supported by a studentship award from the CIHR. D.V.
information, see the Supplemental Experimental Procedures at http://www. is supported by a studentship award from the Heart and Stroke Foundation of
cancercell.org/cgi/content/full/7/1/101/DC1/). Canada (HSFC). D.J.D. is supported by a grant from NIH (NHLBI-R01
HL63224-01A1). Y.B.-D. is supported by grants from NCIC and CIHR. R.J.D.
is supported by grants from the NIH (R01-EY12726).Corneal neovascular micropocket assay
The corneal neovascular micropocket assay was performed as described
(Kenyon et al., 1996); for detailed information, see the Supplemental Experi-
mental Procedures at http://www.cancercell.org/cgi/content/full/7/1/101/
Received: August 17, 2004DC1/.
Revised: October 25, 2004
Accepted: November 18, 2004In vivo angiogenesis assessment by Matrigel plug perfusion assay
Published: January 17, 2005The Matrigel plug perfusion (angiogenesis) assay was performed as pre-
viously described (Klement et al., 2000; Bocci et al., 2003) with some minor
Referencesmodifications (for detailed information, see the Supplemental Experimental
Procedures at http://www.cancercell.org/cgi/content/full/7/1/101/DC1/).
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T.,
Witzenbichler, B., Schatteman, G., and Isner, J.M. (1997). Isolation of putativeCEC and CEP measurements by flow cytometry
progenitor endothelial cells for angiogenesis. Science 275, 964–967.Evaluation of CECs and CEPs was carried out on blood collected by cardiac
puncture, followed by enumeration using four-color flow cytometry as de- Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H.,
scribed previously (Bertolini et al., 2003); for detailed information, see the Inai, Y., Silver, M., and Isner, J.M. (1999). VEGF contributes to postnatal
Supplemental Experimental Procedures at http://www.cancercell.org/cgi/ neovascularization by mobilizing bone marrow-derived endothelial progeni-
tor cells. EMBO J. 18, 3964–3972.content/full/7/1/101/DC1/.
CANCER CELL : JANUARY 2005 109
A R T I C L E
Bertolini, F., Mingrone, W., Alietti, A., Ferrucci, P.F., Cocorocchio, E., Pecca- derived endothelial cell precursors in spontaneous prostate tumors varies
with tumor grade. Cancer Res. 64, 6137–6143.tori, F., Cineri, S., Mancuso, P., Corsini, C., Burlini, A., et al. (2001). Thalido-
mide in multiple myeloma, myelodysplastic syndromes and histiocytosis.
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn,Analysis of clinical results and of surrogate angiogenesis markers. Ann.
A., Heissig, B., Marks, W., Witte, L., et al. (2001). Impaired recruitment ofOncol. 12, 987–990.
bone-marrow-derived endothelial and hematopoietic precursor cells blocks
tumor angiogenesis and growth. Nat. Med. 7, 1194–1201.Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y.,
and Kerbel, R.S. (2003). Maximum tolerable dose and low-dose metronomic
Machein, M.R., Renninger, S., Lima-Hahn, E., and Plate, K.H. (2003). Minorchemotherapy have opposite effects on the mobilization and viability of
contribution of bone marrow-derived endothelial progenitors to the vasculari-circulating endothelial progenitor cells. Cancer Res. 63, 4342–4346.
zation of murine gliomas. Brain Pathol. 13, 582–597.
Bocci, G., Francia, G., Man, S., Lawler, J., and Kerbel, R.S. (2003). Thrombo-
Maisonpierre, P.C., Goldfarb, M., Yancopoulos, G.D., and Gao, G. (1993).spondin-1, a mediator of the antiangiogenic effects of low-dose metronomic
Distinct rat genes with related profiles of expression define a TIE receptor
chemotherapy. Proc. Natl. Acad. Sci. USA 100, 12917–12922.
tyrosine kinase family. Oncogene 8, 1631–1637.
Bocci, G., Man, S.M., Green, S.K., Francia, G., Ebos, J.M.L., du Manoir,
McDonald, D.M., Teicher, B.A., Stetler-Stevenson, W., Ng, S.S., Figg, W.D.,
J.M., Emmenegger, U., Ma, L., Thorpe, P., Davidoff, A.M., et al. (2004).
Folkman, J., Hanahan, D., Auerbach, R., O’Reilly, M., Herbst, R., et al. (2004).
Increased plasma VEGF as a surrogate marker for optimal therapeutic dosing Report from the society for biological therapy and vascular biology faculty of
of VEGFR-2 monoclonal antibodies. Cancer Res. 64, 6616–6625. the NCI workshop on angiogenesis monitoring. J. Immunother. 27, 161–175.
Bouck, N., Stellmach, V., and Hsu, S.C. (1996). How tumors become angio- Miquerol, L., Langille, B.L., and Nagy, A. (2000). Embryonic development is
genic. Adv. Cancer Res. 69, 135–174. disrupted by modest increases in vascular endothelial growth factor gene
expression. Development 127, 3941–3946.Capillo, M., Mancuso, P., Gobbi, A., Monestiroli, S., Pruneri, G., Dell’Agnola,
C., Martinelli, G., Shultz, L., and Bertolini, F. (2003). Continuous infusion of Monestiroli, S., Mancuso, P., Burlini, A., Pruneri, G., Dell’Agnola, C., Gobbi,
endostatin inhibits differentiation, mobilization, and clonogenic potential of A., Martinelli, G., and Bertolini, F. (2001). Kinetics and viability of circulating
endothelial cell progenitors. Clin. Cancer Res. 9, 377–382. endothelial cells as surrogate angiogenesis marker in an animal model of
human lymphoma. Cancer Res. 61, 4341–4344.Cristofanilli, M., Charnsangavej, C., and Hortobagyi, G.N. (2002). Angiogen-
esis modulation in cancer research: novel clinical approaches. Nat. Rev. Morgan, B., Thomas, A.L., Drevs, J., Hennig, J., Buchert, M., Jivan, A.,
Drug Discov. 1, 415–426. Horsfield, M.A., Mross, K., Ball, H.A., Lee, L., et al. (2003). Dynamic contrast-
enhanced magnetic resonance imaging as a biomarker for the pharmacologi-Crosby, J.R., Kaminski, W.E., Schatteman, G., Martin, P.J., Raines, E.W.,
cal response of PTK787/ZK 222584, an inhibitor of the vascular endothelialSeifert, R.A., and Bowen-Pope, D.F. (2000). Endothelial cells of hematopoi-
growth factor receptor tyrosine kinases, in patients with advanced colorectaletic origin make a significant contribution to adult blood vessel formation.
cancer and liver metastases: results from two phase I studies. J. Clin. Oncol.Circ. Res. 87, 728–730.
21, 3955–3964.
Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimo-
Park, J.W., Kerbel, R.S., Kelloff, G.J., Barrett, J.C., Chabner, B.A., Parkinson,vitz-Friedman, A., Fuks, Z., and Kolesnick, R. (2003). Tumor response to
D.R., Peck, J., Ruddon, R.W., Sigman, C.C., and Slamon, D.J. (2004). Ratio-radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155–
nale for biomarkers and surrogate end points in mechanism-driven oncology1159.
drug development. Clin. Cancer Res. 10, 3885–3896.
Gothert, J.R., Gustin, S.E., Van Eekelen, A.M., Schmidt, U., Hall, M.A., Jane,
Parulekar, W.R., and Eisenhauer, E.A. (2004). Phase I trial design for solidS.M., Green, A.R., Gottgens, B., Izon, D.J., and Begley, C.G. (2004). Geneti-
tumor studies of targeted, non-cytotoxic agents: theory and practice. J. Natl.cally tagging endothelial cells in vivo: bone marrow-derived cells do not
Cancer Inst. 96, 990–997.contribute to tumor endothelium. Blood 104, 1769–1777.
Prewett, M., Huber, J., Li, Y., Santiago, A., O’Connor, W., King, K., Over-Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms
holser, J., Hooper, A., Pytowski, B., Witte, L., et al. (1999). Antivascularof the angiogenic switch during tumorigenesis. Cell 86, 353–364.
endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody
inhibits tumor angiogenesis and growth of several mouse and human tumors.Heil, M., Ziegelhoeffer, T., Mees, B., and Schaper, W. (2004). A different
outlook on the role of bone marrow stem cells in vascular growth: bone Cancer Res. 59, 5209–5218.
marrow delivers software not hardware. Circ. Res. 94, 573–574.
Rabascio, C., Muratori, E., Mancuso, P., Calleri, A., Raia, V., Foutz, T., Cinieri,
S., Veronesi, G., Pruneri, G., Lampertico, P., et al. (2004). Assessing tumorHurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, H.,
Helm, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004). angiogenesis: increased circulating VE-cadherin RNA in patients with cancer
indicates viability of circulating endothelial cells. Cancer Res. 64, 4373–4377.Addition of bevacizumab (rhuMab VEGF) to bolus IFL in the first line treatment
of patients with metastatic colorectal cancer: results of a randomized phase
Rafii, S., Lyden, D., Benezra, R., Hattori, K., and Heissig, B. (2002). VascularIII trial. N. Engl. J. Med. 350, 2335–2342.
and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Nat. Rev. Cancer 2, 826–835.Jain, R.K., and Duda, D.G. (2003). Role of bone marrow-derived cells in
tumor angiogenesis and treatment. Cancer Cell 3, 515–516.
Rajantie, I., Ilmonen, M., Alminaite, A., Ozerdem, U., Alitalo, K., and Salven,
P. (2004). Adult bone marrow-derived cells recruited during angiogenesisKenyon, B.M., Voest, E.E., Chen, C.C., Flynn, E., Folkman, J., and D’Amato,
R.J. (1996). A model of angiogenesis in the mouse cornea. Invest. Ophthal- comprise precursors for periendothelial vascular mural cells. Blood 104,
2084–2086 Published online June 10, 2004. 10.1182/blood-2004-01-0336.mol. Vis. Sci. 37, 1625–1632.
Kerbel, R.S., and Kamen, B.A. (2004). Antiangiogenic basis of low-dose Rehman, J., Li, J., Orschell, C.M., and March, K.L. (2003). Peripheral blood
“endothelial progenitor cells” are derived from monocyte/macrophages andmetronomic chemotherapy. Nat. Rev. Cancer 4, 423–436.
secrete angiogenic growth factors. Circulation 107, 1164–1169.
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D., Bohlen,
P., and Kerbel, R.S. (2000). Continuous low-dose therapy with vinblastine Reiher, F.K., Volpert, O.V., Jimenez, B., Crawford, S.E., Dinney, C.P., Henkin,
J., Haviv, F., Bouck, N.P., and Campbell, S.C. (2002). Inhibition of tumorand VEGF receptor-2 antibody induces sustained tumor regression without
overt toxicity. J. Clin. Invest. 105, R15–R24. growth by systemic treatment with thrombospondin-1 peptide mimetics. Int.
J. Cancer 98, 682–689.
Lawler, J., Sunday, M., Thibert, V., Duquette, M., George, E.L., Rayburn, H.,
and Hynes, R.O. (1998). Thrombospondin-1 is required for normal murine Rohan, R.M., Fernandez, A., Udagawa, T., Yuan, J., and D’Amato, R.J.
(2000). Genetic heterogeneity of angiogenesis in mice. FASEB J. 14, 871–pulmonary homeostasis and its absence causes pneumonia. J. Clin. Invest.
101, 982–992. 876.
Ruzinova, M.B., Schoer, R.A., Gerald, W., Egan, J.E., Pandolfi, P.P., Rafii,Li, H., Gerald, W.L., and Benezra, R. (2004). Utilization of bone marrow-
110 CANCER CELL : JANUARY 2005
A R T I C L E
S., Manova, K., Mittal, V., and Benezra, R. (2003). Effect of angiogenesis J.D., and Alani, R.M. (2003). Disruption of Id1 reveals major differences in
angiogenesis between transplanted and autochthonous tumors. Cancer Cellinhibition by Id loss and the contribution of bone-marrow-derived endothelial
cells in spontaneous murine tumors. Cancer Cell 4, 277–289. 4, 291–299.
Stoll, B.R., Migliorini, C., Kadambi, A., Munn, L.L., and Jain, R.K. (2003). ASarao, R., and Dumont, D.J. (1998). Conditional transgene expression in
mathematical model of the contribution of endothelial progenitor cells toendothelial cells. Transgenic Res. 7, 421–427.
angiogenesis in tumors: implications for anti-angiogenic therapy. Blood 102,
Sato, T.N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., 2555–2561.
Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W., and Qin, Y. (1995).
Viloria-Petit, A.M., Miguerol, L., Yu, J.L., Gertenstein, M., Sheehan, C., May,Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel
L., Henkin, J., Lobe, C., Nagy, A., Kerbel, R.S., and Rak, J. (2003). Contrastingformation. Nature 376, 70–74.
effects of VEGF gene disruption in embryonic stem cell-derived versus onco-
Schuch, G., Heymach, J.V., Nomi, M., Machluf, M., Force, J., Atala, A., Eder, gene-induced tumors. EMBO J. 22, 4091–4102.
J.P., Jr., Folkman, J., and Soker, S. (2003). Endostatin inhibits the vascular
Voswinckel, R., Ziegelhoeffer, T., Heil, M., Kostin, S., Breier, G., Mehling,endothelial growth factor-induced mobilization of endothelial progenitor
T., Haberberger, R., Clauss, M., Gaumann, A., Schaper, W., and Seeger, W.cells. Cancer Res. 63, 8345–8350.
(2003). Circulating vascular progenitor cells do not contribute to compensa-
Shaw, J.P., Basch, R., and Shamamian, P. (2004). Hematopoietic stem cells tory lung growth. Circ. Res. 93, 372–379.
and endothelial cell precursors express Tie-2, CD31 and CD45. Blood Cells
Willett, C.G., Boucher, Y., di Tomaso, E., Duda, D.G., Munn, L.L., Tong,Mol. Dis. 32, 168–175.
R.T., Chung, D.C., Sahani, D.V., Kalva, S.P., Kozin, S.V., et al. (2004). Direct
Shibuya, T., and Mak, T.W. (1983). Isolation and induction of erythroleukemic evidence that the VEGF-specific antibody bevacizumab has antivascular
cell lines with properties of erythroid progenitor burst-forming cell (BFU-E) effects in human rectal cancer. Nat. Med. 10, 145–147.
and erythroid precursor cell (CFU-E). Proc. Natl. Acad. Sci. USA 80, 3721–
Ziegelhoeffer, T., Fernandez, B., Kostin, S., Heil, M., Voswinckel, R., Helisch,3725.
A., and Schaper, W. (2004). Bone marrow-derived cells do not incorporate
into the adult growing vasculature. Circ. Res. 94, 230–238.Sikder, H., Huso, D.L., Zhang, H., Wang, B., Ryu, B., Hwang, S.T., Powell,
CANCER CELL : JANUARY 2005 111
